S100 作为帕博利珠单抗治疗转移性黑色素瘤患者生存标志物的相对变化。
Relative Change in S100 as a Biomarker of Survival in Patients With Metastatic Melanoma Treated With Pembrolizumab.
机构信息
Clinical Hospital Centre Zagreb, Department of Oncology, Zagreb, Croatia.
Clinical Hospital Centre Rijeka, Department of Radiotherapy and Oncology, Rijeka, Croatia.
出版信息
Anticancer Res. 2020 Apr;40(4):2157-2163. doi: 10.21873/anticanres.14175.
BACKGROUND/AIM: There is a lack of quality biomarkers of survival for patients with metastatic melanoma treated with immunotherapy. Although the baseline level of S100 has prognostic value, its role during/after therapy in survival is unclear.
PATIENTS AND METHODS
We evaluated patients with metastatic melanoma treated with pembrolizumab with the goal of analysing the relationship between a relative change in S100 level at 12 weeks of immunotherapy and survival.
RESULTS
Patients with a relative change in S100 level >145% at 12 weeks of immunotherapy had significantly shorter progression-free (5.1 vs. 18.5 months, p≤0.0001) and overall survival (5.7 vs. 26.3 months, p<0.0001), further confirmed on multivariate analysis with hazard ratio of 32.25 (95% confidence interval=4.78-217.6, p=0.0004) for overall survival.
CONCLUSION
A relative change in S100 level might be useful as a more precise biomarker of survival for patients with metastatic melanoma treated with pembrolizumab.
背景/目的：接受免疫治疗的转移性黑色素瘤患者缺乏生存质量的生物标志物。虽然基线 S100 水平具有预后价值，但在治疗期间/之后其对生存的作用尚不清楚。
患者和方法
我们评估了接受 pembrolizumab 治疗的转移性黑色素瘤患者，目的是分析免疫治疗 12 周时 S100 水平的相对变化与生存之间的关系。
结果
在免疫治疗 12 周时 S100 水平相对变化>145%的患者无进展生存期（5.1 与 18.5 个月，p≤0.0001）和总生存期（5.7 与 26.3 个月，p<0.0001）显著缩短，多因素分析显示总生存期的危险比为 32.25（95%置信区间为 4.78-217.6，p=0.0004）。
结论
S100 水平的相对变化可能是一种更精确的接受 pembrolizumab 治疗的转移性黑色素瘤患者生存的生物标志物。
Zotero 插件